(19)
(11) EP 4 824 274 A1

(12)

(43) Date of publication:
21.10.2026 Bulletin 2026/43

(21) Application number: 25820767.9

(22) Date of filing: 09.06.2025
(51) International Patent Classification (IPC): 
C12Q 1/02(2006.01)
A61N 1/44(2006.01)
(52) Cooperative Patent Classification (CPC):
A61N 1/44; G01N 33/5088; G01N 2800/52; A61B 2018/00583; H05H 2245/30
(86) International application number:
PCT/CA2025/050792
(87) International publication number:
WO 2025/255650 (18.12.2025 Gazette 2025/51)
(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA
Designated Validation States:
GE KH LA MA MD TN

(30) Priority: 10.06.2024 US 202463658058 P

(71) Applicants:
  • Val-Chum, Société en Commandite
    Québec City, Québec G1P 4P5 (CA)
  • Nexplasmagen Inc.
    Montréal, QC H4A 2T7 (CA)

(72) Inventors:
  • WONG, Philip
    Toronto, Ontario M5M 1G5 (CA)
  • LAFONTAINE, Julie
    Montréal, Québec H2K 3L1 (CA)
  • GLORY, Audrey
    Montréal, Québec H2S 2T9 (CA)
  • LÉVEILLÉ, Valérie
    Montréal, Québec H4A 2T7 (CA)
  • ST-MARTIN, Danny
    Mandeville, Québec J0K 1L0 (CA)

(74) Representative: Patentanwaltskanzlei Vièl & Wieske PartGmbB 
Feldmannstraße 110
66119 Saarbrücken
66119 Saarbrücken (DE)

   


(54) PLASMA-BASED TREATMENT OF CANCER